<DOC>
	<DOCNO>NCT00814736</DOCNO>
	<brief_summary>To investigate safety overall tolerability co-administration two PDE5 inhibitor UK369,003 sildenafil</brief_summary>
	<brief_title>A Randomized , Double-Blinded , Placebo-Controlled , Two-Way Crossover Study Investigate Safety Toleration Single Dose Sildenafil Subjects Receiving Chronic UK-369,0031</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Healthy male subject age 40 55 year , inclusive Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant haematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Loss vision one eye due nonarteritic ischemic optic neuropathy ( NAION ) regardless whether event temporally associate use PDE5 inhibitor .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>